nach oben

Erschienen in:

01.03.2015 | Original article

Increase of circulating stromal cell-derived factor-1 in heart failure patients

verfasst von: K. Liu, S. Yang, M. Hou, T. Chen, J. Liu, B. Yu, MD, PhD

Erschienen in: Herz | Sonderheft 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The role of circulating stromal cell-derived factor-1 (SDF-1) in heart failure (HF) has not been defined. The aim of this study was to examine the circulating SDF-1 levels in hospitalized heart failure (HHF) patients.

Methods

Circulating SDF-1 and other clinical variables, including N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and echocardiographic parameters, were measured in HHF patients (n = 69) and healthy control subjects (n = 35).

Results

The circulating SDF-1 level was significantly greater in patients with HF (5,101 ± 1,977 pg/ml) compared with the control subjects (1,879 ± 1,417 pg/ml; p < 0.001). Circulating SDF-1 levels were positively correlated with NT-proBNP (r = 0.46 p < 0.001) and CRP (r = 0.53 p < 0.001) levels, and negatively correlated with left ventricular ejection fraction values (r = − 0.41, p < 0.001).

Conclusion

The level of circulating SDF-1 increases in HHF patients.

Cleland JG, Khand A, Clark A (2001) The heart failure epidemic: exactly how big is it? Eur Heart J 22:623–626CrossRefPubMed

Go AS, Mozaffarian D, Roger VL et al (2013) Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127:143–152CrossRefPubMed

Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167CrossRefPubMed

Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954CrossRefPubMed

Suleiman M, Khatib R, Agmon Y et al (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47:962–968CrossRefPubMed

Kimmenade RR van, Januzzi JL Jr, Ellinor PT et al (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–1224CrossRefPubMed

D’Apuzzo M, Rolink A, Loetscher M et al (1997) The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 27:1788–1793CrossRef

Nagasawa T, Kikutani H, Kishimoto T (1994) Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 91:2305–2309CrossRefPubMedCentralPubMed

Nagasawa T, Nakajima T, Tachibana K et al (1996) Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A 93:14726–14729CrossRefPubMedCentralPubMed

10.

Ratajczak MZ, Zuba-Surma E, Kucia M et al (2006) The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20:1915–1924CrossRefPubMed

11.

Lapidot T, Petit I (2002) Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30:973–981CrossRefPubMed

12.

Aiuti A, Tavian M, Cipponi A et al (1999) Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol 29:1823–1831CrossRefPubMed

13.

Aiuti A, Turchetto L, Cota M et al (1999) Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Blood 94:62–73PubMed

14.

Ceradini DJ, Kulkarni AR, Callaghan MJ et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864CrossRefPubMed

15.

Tang YL, Zhu W, Cheng M et al (2009) Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 104:1209–1216CrossRefPubMedCentralPubMed

16.

Sweeney EA, Lortat-Jacob H, Priestley GV et al (2002) Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 99:44–51CrossRefPubMed

17.

Zhang M, Mal N, Kiedrowski M et al (2007) SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21:3197–3207CrossRefPubMed

18.

Hu X, Dai S, Wu WJ et al (2007) Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 116:654–663CrossRefPubMedCentralPubMed

19.

Abbott JD, Huang Y, Liu D et al (2004) Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110:3300–3305CrossRefPubMed

20.

Elmadbouh I, Haider H, Jiang S et al (2007) Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 42:792–803CrossRefPubMedCentralPubMed

21.

Deglurkar I, Mal N, Mills WR et al (2006) Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther 17:1144–1151CrossRefPubMed

22.

Sundararaman S, Miller TJ, Pastore JM et al (2011) Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Ther 18:867–873CrossRefPubMedCentralPubMed

23.

Askari AT, Unzek S, Popovic ZB et al (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362:697–703CrossRefPubMed

24.

Stellos K, Bigalke B, Langer H et al (2009) Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34 + progenitor cells. Eur Heart J 30:584–593CrossRefPubMed

25.

Gazitt Y, Liu Q (2001) Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34 + cells in mobilized peripheral blood of non-Hodgkin’s lymphoma patients. Stem Cells 19:37–45CrossRefPubMed

26.

Groves MD, Hess KR, Puduvalli VK et al (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94:229–234CrossRefPubMed

27.

Wurster T, Stellos K, Geisler T et al (2012) Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke? Eur J Neurol 19:395–401CrossRefPubMed

28.

Loader B, Stokic D, Riedl M et al (2008) Combined analysis of audiologic performance and the plasma biomarker stromal cell-derived factor 1a in type 2 diabetic patients. Otol Neurotol y 29:739–744CrossRef

29.

Li SL, Lin W, Zhang Y et al (2012) Stromal cell-derived factor-1alpha as a novel biomarker for hyperlipidemia. Tohoku J Exp Med 228:355–363CrossRefPubMed

30.

Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed

31.

Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694CrossRefPubMed

32.

Levesque JP, Hendy J, Takamatsu Y et al (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187–196CrossRefPubMedCentralPubMed

33.

Laske C, Stellos K, Eschweiler GW et al (2008) Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer’s disease: a contribution to a deficient hematopoietic brain support? J Alzheimers Dis 15:83–95PubMed

34.

Kim HK, Kim JE, Chung J et al (2007) Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. Thromb Res 120:559–566CrossRefPubMed

35.

Matsuda M, Morita Y, Hanamoto H et al (2004) CD34 + progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia 18:1038–1040CrossRefPubMed

36.

Jorbenadze R, Schleicher E, Bigalke B et al (2014) Expression of platelet-bound stromal-cell derived factor-1 (SDF-1) and number of CD34(+) progenitor cells in patients with congestive heart failure. Platelets 25:409–415CrossRefPubMed

37.

Lee SH, Wolf PL, Escudero R et al (2000) Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342:626–633CrossRefPubMed

38.

Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365:537–547CrossRefPubMed

39.

Yndestad A, Damas JK, Oie E et al (2007) Role of inflammation in the progression of heart failure. Curr Cardiol Rep 9:236–241CrossRefPubMed

40.

Torre-Amione G (2005) Immune activation in chronic heart failure. Am J Cardiol 95:3C–8C; (discussion 38C–40C)CrossRefPubMed

41.

Deswal A, Petersen NJ, Feldman AM et al (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103:2055–2059CrossRefPubMed

42.

Santiago B, Baleux F, Palao G et al (2006) CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther 8:R43CrossRefPubMedCentralPubMed

43.

Wang A, Guilpain P, Chong BF et al (2010) Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum 62:3436–3446CrossRefPubMed

44.

Nanki T, Hayashida K, El-Gabalawy HS et al (2000) Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 + T cell accumulation in rheumatoid arthritis synovium. J Immunol 165:6590–6598CrossRefPubMed

45.

Calderon TM, Eugenin EA, Lopez L et al (2006) A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177:27–39CrossRefPubMed

46.

Krumbholz M, Theil D, Cepok S et al (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129:200–211CrossRefPubMed

47.

Weiss JM, Cufi P, Bismuth J et al (2013) SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology 218:373–381CrossRefPubMed

48.

Banisadr G, Skrzydelski D, Kitabgi P et al (2003) Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur J Neurosci 18:1593–1606CrossRefPubMed

49.

Wei SG, Zhang ZH, Yu Y et al (2012) Central actions of the chemokine stromal cell-derived factor 1 contribute to neurohumoral excitation in heart failure rats. Hypertension 59:991–998CrossRefPubMedCentralPubMed

Titel: Increase of circulating stromal cell-derived factor-1 in heart failure patients
verfasst von: K. Liu
S. Yang
M. Hou
T. Chen
J. Liu
B. Yu, MD, PhD
Publikationsdatum: 01.03.2015
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe Sonderheft 1/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-014-4169-z

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2015

The role of fQRS in coronary artery disease

Guideline-adherent therapy in patients with acute coronary syndromes

Prevalence of coronary artery fistulae after cardiac surgery

Predictive value of the novel risk score BETTER (BiomarkErs and compuTed Tomography scorE on Risk stratification) for patients with unstable angina